Phaseline

Targets › RSV

RSV: drug programs, companies and trials

9 programs from 7 companies in 18 trials: 13 Phase 1, 4 Phase 2, 1 Phase 3; Infectious disease, Vaccines, Respiratory; next expected readout Dec 2026.

Open in Phaseline: the race on RSV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MAXVAX Biotechnology Limited Liability CompanyRecombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dose
Recombinant RSV vaccine
RSVPhase 3Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus InfectionsFeb 2027
Enanta PharmaceuticalsZelicapavir
RSV non-fusion replication inhibitor
RSVPhase 2RSV Infection; RSVDec 2026
GSKAdjuvanted RSVPreF3 vaccine
RSV PreF3 protein subunit vaccine with adjuvant
RSVPhase 2Respiratory Syncytial Virus InfectionsJan 2027
Shenzhen Shenxin BiotechnologyRespiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)
Bivalent mRNA vaccine targeting respiratory syncytial virus
RSVPhase 2Respiratory Syncytial Virus (RSV) Infection; Respiratory Syncytial Virus InfectionsApr 2027
SanofiInvestigational hMPV/RSV vaccine
mRNA vaccine encapsulated in lipid nanoparticle targeting hMPV and RSV
HMPV, RSVPhase 1Human Metapneumovirus ImmunizationJan 2027
ModernaTXmRNA-1365 (Profile 2)
mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)
RSV, HMPVPhase 1Respiratory Syncytial Virus (RSV); Respiratory Syncytial VirusJul 2027
AstraZenecaAZD6489
RSV recombinant prefusion F protein virus-like particle (VLP) vaccine
RSVPhase 1RSV Respiratory Syncytial VirusAug 2027
SanofiRSV + HMPV Candidate Vaccine
Live attenuated or recombinant viral vaccine against respiratory syncytial virus and human
RSV, HMPVPhase 1Respiratory Syncytial Virus ImmunizationMay 2028
ModernaTXmRNA-1345
mRNA vaccine targeting respiratory syncytial virus (RSV)
RSVPhase 1Respiratory Syncytial VirusAug 2029

Conditions

Respiratory Syncytial Virus (RSV) (4) Human Metapneumovirus Immunization (4) Respiratory Syncytial Virus Infections (3) Respiratory Syncytial Virus (2) RSV Respiratory Syncytial Virus (1) Respiratory Syncytial Virus Immunization (1) RSV Infection (1) RSV (1) Respiratory Syncytial Virus (RSV) Infection (1)

Modalities

other (6), mixed (2), small molecule (1)

Companies

Sanofi (2) ModernaTX (2) AstraZeneca (1) MAXVAX Biotechnology Limited Liability Company (1) Enanta Pharmaceuticals (1) Shenzhen Shenxin Biotechnology (1) GSK (1)

Related targets

HMPV (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.